Ranbaxy Laboratories, Inc.

Sun Pharmaceutical Industries Limited

Rajesh Kumar Thaper

Mohan Prasad

Swargam Sathyanarayana

Yatendra Kumar

Jagdev Singh Jaryal

Jag Mohan Khanna

S M Kumar

Mahavir Singh Khanna

Anu Mittal

Satyananda Misra

Anmol Kumar Ray

Anandam Vempali

Balaguru Murugesan

Saridi Madhava Dileep Kumar

Sudhir Singh Sanwal

Munish Kapoor

S M Dileep Kumar

Rakesh Singh

Gopal Singh Bisht

Sachin Deorao Zade

Ajay Shankar Singh

The present invention relates to processes for the preparation of dasatinib and its intermediates.

Process for the preparation of dasatinib and its intermediates

The present invention relates to a process for the preparation of crystalline Form I of methanesulfonate salt of dabigatran etexilate. (Formula (I)). The present invention does not require the isolation of the dabigatran etexilate intermediate. 

Process for the preparation of crystalline form I of methanesulfonate salt of dabigatran etexilate

The present invention relates to the salts of dexlansoprazole in amorphous form. The present invention further relates to processes for the preparation of salts of dexlansoprazole.

Salts of dexlansoprazole and their preparation

The present invention relates to a process for the preparation of crystalline dexlansoprazole.

Process for the preparation of dexlansoprazole

The present invention relates to crystalline forms of bosentan salts and processes for their preparation.(FORMULA) 

Crystalline forms of bosentan salts and processes for their preparation

The present invention provides dimethyl sulphoxide solvate of 4-(4-{3-[4-chloro-3 -(trifluoromethyl)phenyl]ureido}phenoxy)-N-methylpyridine-2-carboxamide, process for its preparation, pharmaceutical composition comprising it and its use for the treatment of cancer. The present invention also provides a novel HPLC method for the identification, quantification and isolation of related substances of sorafenib.

Sorafenib dimethyl sulphoxide solvate

The present invention provides amorphous and crystalline forms of acid addition salts of sorafenib, pharmaceutical compositions comprising them, and their use for the treatment of cancer. The present invention also provides processes for the preparation of acid addition salts of sorafenib.

Polymorphs of sorafenib acid addition salts

The present invention provides a process for the preparation of sorafenib tosylate, comprising contacting sorafenib free base with p-toluenesulphonic acid in water.

Process for the preparation of sorafenib tosylate

The present invention provides amorphous and crystalline forms of acid addition salts of sorafenib, pharmaceutical compositions comprising them and their use for the treatment of cancer. The present invention also provides processes for the preparation of acid addition salts of sorafenib.

The present invention provides sorafenib ethane sulphonate, process for its preparation, pharmaceutical composition comprising sorafenib ethane sulphonate and its use for the treatment of cancer. Formula (III). 

Sorafenib ethylsulfonate salt, process for preparation and use

The present invention relates to a process for preparation of erlotinib of Formula I or its pharmaceutically acceptable salt thereof. The present invention also relates to process for the preparation of erlotinib trifluoroacetate. The present invention also relates to a nove-ICrystalline form of erlotinib trifluoroacetate designated as Form E and process for its preparation. The present invention further relates to process for the preparation of erlotinib hydrochloride from erlotinib trifluoroacetate. 

Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof

The present invention relates to a novel methyl analog of simvastatin, which has the ability to inhibit the synthesis of cholesterol. The compound of the present invention holds promise for the treatment and prophylaxis of hypercholesterolemia and of various cardiac disorders. The invention also relates to a process for making the novel compound.

Methyl analogs of simvastatin as novel HMG-CoA reductase inhibitors

A process for the preparation of amorphous atorvastatin calcium and hydrates thereof which comprises: (a) dissolving crystalline atorvastatin calcium in a non-hydroxylic solvent; (b) adding a non-polar hydrocarbon anti-solvent or adding the dissolved atorvastatin to the non-polar anti-solvent to precipitate out atorvastatin calcium; and (c) removing the solvent by filtration to afford amorphous atorvastatin calcium.

Process for the production of amorphous atorvastatin calcium

A novel process of lactonizaton in the preparation of statins (e.g., the HMG--CoA reductase inhibitors lovastatin and simvastatin) employs very mild reaction conditions. The improved process comprises dissolving the open ring hydroxy acid form of the statins in an organic solvent by heating at a temperature, which ranges from ambient to reflux of the solvent, under anhydrous conditions to produce a solution, treating the solution with a mild catalyst at a temperature from about ambient to 50.degree. C., and adding water to the solution to cause the statins in lactone form to crystalize from the reaction mixture. The mild catalyst used in the reaction is a salt of an organic base with an organic or inorganic acid, such as pyridine hydrobromide, pyridine hydrochloride, or pyridinium, p-toluene sulfonate. The organic solvent comprises a lower alkanol, a non-alcoholic polar solvent, or a mixture of the two.

Process of lactonization in the preparation of statins

An improved process of lactonization in the preparation of statins (e.g., the HMG--CoA reductase inhibitors lovastatin and simvastatin) employs very mild reaction conditions. The improved process comprises treating the open ring hydroxy acid form of the statins with an excess of acetic acid and in the absence of a strong acid catalyst under mild heating conditions (e.g., ambient to 55.degree. C.), and adding an anti-solvent to the reaction mixture, thereby causing the statins in lactone form to crystalize from the reaction mixture. The acetic acid serves as both a solvent and a catalyst for the lactonization reaction.

Growing community of inventors

Jammu, India

Rajesh Kumar Thaper